目的 探讨厄洛替尼致睫毛异常生长的发生情况和临床特点,为其临床安全用药提供参考。方法 检索中国知网(CNKI)、维普中文科技期刊数据库(VIP)、万方数据库、PubMed、Medline数据库2004年1月-2022年2月收录的厄洛替尼致睫毛异常生长相关文献,进行统计分析。结果 纳入统计文献共21篇,涉及26例患者,其中,60岁以上老年患者17例,占比65.38%;患者睫毛异常生长多发生于用药后6个月内(20例),占比76.92%;临床表现方面,睫毛异常增长伴卷曲、倒睫引发角膜刺激征5例,出现睑板腺堵塞、眼睑炎和不自主流泪2例,导致严重的眼部损害症状,如角膜溃疡、糜烂及视觉障碍4例;经积极对症处理或停药后得到解决的患者21例;未予处理5例。结论 厄洛替尼引发睫毛异常生长并非厄洛替尼的限制性副作用,但任其发展,可引发倒睫、眼角膜上皮损伤,进而出现角膜溃疡、穿孔等,最终可致盲。故临床医师应严格按照适应证及推荐剂量给药,重视厄洛替尼引发的睫毛异常生长导致的严重后果。

Objective Investigate the occurrence and clinical characteristics of abnormal eyelash growth caused by erlotinib, so as to provide reference for using it on clinical aspects safely. Methods Literatures related to abnormal eyelash growth caused by erlotinib collected by CNKI, VIP, Wanfang, PubMed, and Medline database as of Feburary 2022 were searched for statistical analysis. Results A total of 21 statistical literatures were included, involving 26 patients. Among them, the proportion of elderly patients over 60 years old was the highest (19 cases), accounting for 65.38%. The abnormal growth of eyelashes occurred within 6 months after treatment (20 cases), accounting for 76.92%. In terms of clinical manifestations, abnormal growth of eyelashes with curl and trichiasis caused corneal irritation in 5 cases, tarsal gland blockage, blepharitis, and involuntary tears in 2 cases, resulting in serious ocular damage symptoms, such as corneal ulcer, erosion and visual impairment in 4 cases. 21 Cases were solved after active symptomatic treatment or drug withdrawal; 5 cases were not treated. Conclusion Abnormal eyelash growth caused by erlotinib is not the limiting side effect of erlotinib, but its development can lead to trichiasis, corneal epithelial damage, corneal ulcer, perforation, etc., and finally blindness. Therefore, clinicians should strictly follow the indications and recommended dose, and pay attention to the serious consequences caused by abnormal eyelash growth caused by erlotinib.

R979.1